Strs Ohio Purchases New Position in Repligen Corporation $RGEN

Key Points

• Strs Ohio has acquired 47,700 shares of Repligen Corporation, valued at approximately $6.07 million, representing about 0.08% ownership in the company.
• Recent analysts' ratings show a mix of evaluations for Repligen, with eight investment analysts issuing a Buy rating and four a Hold rating, while the average price target is set at $166.67.
• Repligen's stock recently declined by 5.0%, currently trading at $113.54, following a quarterly earnings report that missed analysts' expectations.

Strs Ohio acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 47,700 shares of the biotechnology company's stock, valued at approximately $6,069,000. Strs Ohio owned 0.08% of Repligen at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Alliance Wealth Advisors LLC UT grew its holdings in Repligen by 2.5% during the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock valued at $468,000 after purchasing an additional 89 shares during the period. State of Michigan Retirement System boosted its holdings in shares of Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after acquiring an additional 100 shares during the period. Louisiana State Employees Retirement System boosted its holdings in shares of Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock worth $1,858,000 after acquiring an additional 100 shares during the period. State of Wyoming boosted its holdings in shares of Repligen by 5.2% in the first quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock worth $297,000 after acquiring an additional 115 shares during the period. Finally, Signaturefd LLC boosted its holdings in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 128 shares during the period. 97.64% of the stock is owned by institutional investors.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. Wells Fargo & Company dropped their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective for the company. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $166.67.

Repligen Price Performance

NASDAQ RGEN traded down $2.08 during trading hours on Friday, reaching $122.30. 1,103,283 shares of the stock traded hands, compared to its average volume of 738,209. The stock has a 50 day simple moving average of $119.78 and a two-hundred day simple moving average of $126.72. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The company has a market cap of $6.88 billion, a price-to-earnings ratio of -489.18, a price-to-earnings-growth ratio of 2.29 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.